Background. Oral oseltamivir administration is effective treatment for influenza in adults. This study was conducted to determine the efficacy, safety and tolerability of oseltamivir in children with influenza.
INTRODUCTION
Influenza is a common respiratory infection in children. Depending on age, annual attack rates in children are ϳ1.5-to 3.0-fold higher than in adults. 1, 2 Influenza causes substantial morbidity, including upper and lower respiratory complications, and it increases health care contacts. 3 Otitis media is a common sequela of influenza infection in children, occurring in 20% or more of those Յ6 years. 4 Children with underlying health problems, particularly those immunocompromised, as well as healthy children have an increased incidence of hospitalization because of influenza. 5, 6 Current treatment options of influenza in children have limitations. The M2 inhibitors, amantadine and rimantadine, have limited clinical use in pediatrics because of the rapid development of viral resistance, lack of activity against influenza B and only moderate clinical benefit without documented effects on complications. [7] [8] [9] [10] The neuraminidase inhibitors zanamivir and oseltamivir are active against influenza A and B viruses and are approved for use in adults. [11] [12] [13] [14] Recently, zanamivir was licensed by the United States Food and Drug Administration for treatment of influenza in children Ն7 years of age. This drug is not orally active and is administered by inhalation, which consequently limits its potential use in children Յ5 years. 15, 16 Oseltamivir is orally bioavailable in children age 1 to 12 years and is efficiently metabolized to the active carboxy metabolite. Pharmacokinetic modeling in children indicated that a dose of oseltamivir 2 mg/kg would result in cumulative plasma concentrations over time similar to the dosage demonstrated to be safe and effective in adults. 13, 14 Consequently we conducted a multicenter trial to determine the safety and efficacy of oral oseltamivir in otherwise healthy children (age 1 through 12 years) with acute influenza.
METHODS
A double blind, randomized, placebo-controlled, multicenter trial was conducted during the influenza season of 1998 to 1999 in the United States (70 sites) and Canada (10 sites). This study was conducted in accordance with the principles of the Declaration of Helsinki (amended). Institutional review boards approved the protocol at each center. All caregivers provided written informed consent before enrollment. Patients also gave written consent if they were old enough to understand the risks and benefits of the study.
Study population. When surveillance demonstrated that influenza was circulating in the community, children between the ages of 1 and 2 years, presenting within 48 h of illness onset and having an oral/otic temperature Ն100°F (37.8°C) and at least one respiratory symptom (cough or coryza), were offered enrollment into the study. Study exclusion criteria included: children with respiratory syncytial virus infection (rapid antigen); hospitalized Ͼ24 h; evidence of a poorly controlled systemic illness; immunosuppressed (drugs, transplant recipient, malignancy or human immunodeficiency virus infection); or history of acetaminophen (paracetamol) allergy. Influenza therapy (within 4 weeks) and participation in a clinical trial with an investigational drug were also exclusion criteria. Influenza immunization was not an exclusion criterion.
Study design. A physical examination was performed at baseline. A block randomization by site was used. Children were randomized to receive either placebo or liquid oseltamivir at 2 mg/kg/dose (to a maximum of 100 mg/dose) twice daily for 10 doses and were stratified for the presence of otitis media at enrollment. All patients were offered acetaminophen for symptomatic relief.
A physical examination was performed, and blood samples were taken for standard hematologic and clinical biochemistry assays at baseline and Day 6.
Tympanometry was performed at enrollment and on Days 6, 10 and 28. Secondary complications (defined as otitis media, sinusitis, bronchitis or pneumonia requiring physician-prescribed antibiotic intervention that commenced on or after Study Day 3) were recorded. In addition total antibiotic usage, regardless of diagnosis, was recorded. Response to therapy was recorded by the caregiver on a diary card with three major components: the patient's temperature; an assessment of 18 influenza symptoms, as shown in Table 1 ; and the ability of the child to return to day care/school and/or resumption of their normal "preillness" daily activity. Diary cards also recorded the administration of analgesics/ antipyretics (acetaminophen) and compliance with the daily regimen of study medication.
The 18-influenza symptoms evaluation was assessed using the validated Canadian Acute Respiratory Infection and Flu Scale (CARIFS). 17 Each symptom was graded as 0 ϭ no problem, 1 ϭ minor, 2 ϭ moderate, 3 ϭ severe or not evaluable. In the computation of the total CARIFS at each assessment, a recording of not evaluable was not included in the total score. The three components recorded on the diary card were assessed twice daily (at the same time as drug administration during the treatment period) for the first 10 days and once daily thereafter. In addition during the first 3 days, temperature was recorded at a third time, namely midway between the administration of daytime doses. Virologic methods. Nasal and throat swabs were obtained for detection of influenza virus at enrollment and on Days 6 and 10. A subset of patients had additional swabs taken on Days 2 and 4 for virus isolation. Swabs were placed in a viral transport medium (Microtest, Atlanta, GA) and shipped by air express to a central laboratory (Viromed Laboratories, Inc., Minneapolis, MN). Specimens were inoculated onto rhesus monkey kidney cells. 18, 19 Isolates were confirmed by immunofluorescence methods with monoclonal antibodies. 19 Serum hemagglutination inhibition (HAI) antibody titers 19 were measured in paired acute (enrollment) and convalescent (Day 28) blood samples. Influenza infection was defined by virus recovery and/or a 4-fold rise in the HAI antibody titers. Viral isolates from patients were used to investigate the potential for development of resistance based on analysis by neuraminidase inhibition phenotype.
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Data analyses. Randomized patients who received one dose of medication comprised the intent to treat population (ITT). Patients with laboratory-confirmed influenza formed the intent to treat infected (ITTI) population. Efficacy analyses were performed on the ITTI population, and tolerability was assessed in the safety population. All data were recorded on standardized case record forms
The primary endpoint was the time to resolution of illness. This was defined as the length of time from the Unable to get out of bed start of the treatment to the first time at which the following conditions were resolved simultaneously and remained so for at least 24 h: (1) cough and nasal congestion reported as no or minor problem; (2) return to day care/school, or resumption of preillness daily activity; and (3) temperature Յ98.9 o F (37.2 o C). Data from patients who withdrew before resolution of all the above conditions were censored at the time of the last assessment (i.e. they contributed to the analysis of time to alleviation of illness until withdrawal from the study).
Other endpoints included time to return to normal health and activity (a component of the primary endpoint), the incidence of secondary illnesses (i.e. otitis media, etc.), time to alleviation of all CARIFS symptoms and the severity of illness [area under the curve (AUC) for the total CARIFS scores]. Other analyses explored effects on individual symptoms, acetaminophen and antibiotic use, viral shedding and hospitalization rates. Analyses were not adjusted for multiple comparisons.
A weighted Mantel-Haenszel test, which accounts for censored data, was used for time to event analyses. The test was stratified for geographic region and the presence of otitis media at enrollment. Regions were defined on a geographic basis to give ϳ40 subjects per treatment group in the ITTI population and identified before unblinding. The weighting scheme used the generalized Gehan-Wilcoxon weights for which the weighting is equal to the number in the risk group. The results are reported for median duration for each treatment group with 95% confidence intervals. Estimates of the difference in median duration were obtained from the Kaplan-Meier curves. Estimates of the intergroup variability were obtained through bootstrapping 21 to provide a 95% confidence interval. For the severity of illness endpoint AUC for total CARIFS symptoms was analyzed by an extended Wilcoxon rank sum (van Elteren) test, stratified for region, presence of otitis media at baseline and age (Յ2, 3 to 5, 6 to 12). The relative risk (and 95% confidence interval) of developing otitis media was computed by comparison of proportions. All analyses were performed with SAS (Version 6.12) systems and procedures (SAS Institute, Cary, NC).
Sample size. The sample size calculation was based on adult treatment studies, assuming an estimated treatment difference of 1.25 days (SD, 4 days). A cohort of 170 infected patients per treatment group was required to detect this treatment difference with a two group t test at the 5% level of significance and an 80% power. On the basis of an influenza infection rate of ϳ50%, this study was designed to recruit ϳ680 patients.
RESULTS
A total of 698 patients from 80 centers in the United States and Canada were enrolled into the study. Three patients withdrew before taking any medication. For 2 children parental consent was withdrawn for one; for the other phlebotomy was refused. The demographics of the remaining 695 patients were similar for the placebo and oseltamivir recipients ( Table 2 ). Children 2 years of age or younger accounted for a large proportion of both groups (placebo 26%, oseltamivir 23%). Influenza was diagnosed in 452 (65%) patients, of whom 235 received placebo and 217 received oseltamivir (ITTI population). The demographic characteristics of the ITTI population were similar to that for the ITT population.
The clinical characteristics for the ITTI patients are shown in Table 3 . Only 3% of children were immunized against influenza. Influenza A, and less often influenza B, occurred in comparable proportions of the groups. Otitis media was diagnosed in 15 to 16% at enrollment. The median duration of illness before the first dose of medication was similar in both groups. No efficacy information was available from 10 placebo-treated and 8 oseltamivir-treated patients, and a further 13 placebo-treated and 15 oseltamivir-treated patients data were censored because of missing data points.
Clinical efficacy. Among influenza-infected children oseltamivir therapy reduced the median time to resolution of illness by 36 h (26%; P Ͻ 0.0001) compared with placebo (Table 4) . A difference in the proportion of children who improved was apparent within 24 h after initiating therapy and persisted until ϳ480 h (Day 20), at which point the two groups were comparable, as shown in Figure 1 . The time to resolution of illness was shorter in oseltamivir than in placebo recipients for all age groups analyzed, as shown in Table 4 . The individual components for alleviation of illness were all achieved earlier in oseltamivir than in placebo recipients (Table 4) .
For the entire ITT population (all randomized children) oseltamivir treatment also significantly reduced the median time to resolution of illness by 21 h (17%, Influenza-infected children who received oseltamivir had a significant reduction in the median duration of total CARIFS symptoms compared with placebo recipients (P Ͻ 0.0001) ( Table 4) . Similarly the extent and severity of illness, measured by the AUC of the total CARIFS symptoms, was reduced by 29% in oseltamivir compared with placebo recipients (P ϭ 0.002), as shown in Table 4 . Individual symptoms such as fever, cough and coryza also resolved faster in patients who received oseltamivir, with median reductions in duration of 36% (P Ͻ 0.0001), 45% (P ϭ 0.0008) and 34% (P ϭ 0.09), respectively, as shown in Table 4 . Median total acetaminophen consumption was 31% less for subjects in the oseltamivir (40 mg/kg) compared with the placebo (59 mg/kg) groups (P ϭ 0.002).
Among 144 (32%) children infected with influenza B, subgroup analyses showed a significant reduction in the median durations of fever, cough and coryza (placebo 100 h, oseltamivir 73 h; P ϭ 0.01) and of the 18 symptoms reported on the CARIFS (placebo 96 h, oseltamivir 56 h; P ϭ 0.008).
The incidence of physician-diagnosed complications requiring antibiotic treatment developing after Study Day 2 was reduced by 40% in the oseltamivir treatment group (36 of 217, 17%) compared with placebo recipients (65 of 235, 28%; P ϭ 0.005). The relative risk of developing otitis media, the most common secondary illness in both groups, was 0.56 (95% confidence interval, 0.36 to 0.87), a 44% reduction for oseltamivir recipients (26 of 217, 12%) compared with those taking placebo (50 of 235, 21%). Otitis media was confirmed by tympanometry in a proportion of patients; the overall concordance between clinical diagnosis and tympanometric confirmation of otitis media was 93% (100% in the placebo group and 81% in oseltamivir group). The incidence of tympanometrically confirmed otitis media was 37 of 200 (18.5%) placebo recipients and 17 of 183 (9.3%) oseltamivir recipients, a relative risk reduction of 50%. The proportion of patients receiving physicianprescribed antibiotic treatment was also significantly lower in the oseltamivir group (68 of 217, 31%) compared with placebo recipients (97 of 235, 41%; P ϭ 0.03).
No patient in the oseltamivir group and two patients in the placebo group required hospitalization during this study. One child was hospitalized for dehydration and one for ingestion of a caustic substance.
Virologic measures. The shortened clinical course of influenza was accompanied by an accelerated decline in virus recovery from the upper respiratory tract. More than 90% of patients in each group shed virus at enrollment (placebo 207 of 231, oseltamivir 191 of 213). The majority of patients had nose/throat swabs taken on Days 2, 4 and 6 of the study. In this population, by Day 4 only 51 of 93 (55%) of patients receiving oseltamivir shed virus compared with 72 of 105 (69%) of placebo recipients. Oseltamivir treatment significantly reduced viral titers compared with placebo (median AUC virus titers, in which TCID50 is 50% tissue culture-infective dose: placebo, 303 log 10 TCID 50 ϫ hours/ml; oseltamivir: 243 log 10 TCID 50 ϫ hours/ml; P ϭ 0. 04) (Fig. 2) .
Fourfold or greater rises in serum HAI antibody titer occurred in 97% of placebo and 92% of oseltamivir recipients. There were no differences in convalescent geometric mean titer as indicated in Table 4 . Oseltamivir treatment therefore did not inhibit the antibody response to naturally acquired influenza infection.
No evidence of influenza virus resistant to oseltamivir was detected at baseline (n ϭ 385) based on sensitivity of the viral neuraminidase to inhibition by Ro 64-0802, the active metabolite of oseltamivir. Similarly no evidence of resistance was found in placebo recipients at any time during the study (n ϭ 217). In oseltamivir recipients 10 posttreatment influenza isolates had a 50% inhibitory concentration for neuraminidase inhibition higher than pretreatment values, indicating in vitro resistance. The overall incidence was 10 of 182 (5.5%) of oseltamivir-treated patients who were culture-positive and for whom satisfactory viral neuraminidase sensitivity assay data were obtained. Analysis of these samples confirmed the associated genotypic mutations to be those previously described from in vitro studies and in adults. 22, 23 The mutations identified in this study were the arginine to lysine mutation at p292 (R292K) in 8 children, a glutamate to valine mutation at p119 (E119V) in 1 child and a histidine to tyrosine mutation at p274 (H274Y) in 1 child. The variants were identified on Study Day 6 in 9 cases and Day 4 of treatment in one case. No variants were detectable by Study Day 10. The clinical course of disease in these patients was no different than that of children with isolates, which remained susceptible to oseltamivir. There was no evidence of resistance in influenza B isolates. Safety and tolerability. Oseltamivir treatment was generally well-tolerated with an incidence of adverse events comparable with those of the placebo recipients. No differences were seen in laboratory parameters and vital signs between the groups. More than 90% of children took all scheduled doses, regardless of randomization group. The most common adverse events were those involving the gastrointestinal system: emesis was reported in 14.3% of patients receiving oseltamivir compared with 8.5% receiving placebo; however, ϳ1% of children discontinued the study because of this adverse event. The incidence of diarrhea was higher in placebo (10.5%) compared with oseltamivir recipients (8.8%). Five patients (0.7%) reported serious adverse events during treatment (placebo: pneumonia, one; dehydration, one; oseltamivir: pneumonia, two; dehydration, one); none of these events were considered to be related to the study drug and all resolved without sequelae. The overall discontinuation rate as a result of an adverse event was low and comparable in both groups: four (1.1%) for placebo and six (1.8%) for oseltamivir recipients.
DISCUSSION
The severity of influenza is illustrated by the outcome of the placebo recipients. Children in the placebo group in this study experienced influenza symptoms for a median of 5.7 days after enrollment. Because the median duration of disease was slightly greater than 1 day before entry, disease in these children lasts for 1 week. Complications in children are common and include pneumonia and otitis media. 3 Indeed in this study nearly 30% of placebo recipients had physiciandiagnosed complications, with otitis media developing in Ͼ20%, all of whom received antibiotic therapy. Furthermore the placebo recipients excreted large quantities of virus for at least 4 days, providing a reservoir for spread within the community. Because influenza infections are an important cause of illness during the winter months and increase the burden of the primary health care provider, 1 attempts at both prevention and treatment would be of significant value to the health care system. To this end oseltamivir therapy significantly improved outcome. This is the first study to demonstrate the efficacy and tolerability of an antiviral for the therapy of influenza A or B illness in children. Oseltamivir, when given within 48 h of the onset of symptoms, decreased the time to resolution of illness by 26% (1.5 days) and overall severity of illness by 29% for influenza-infected. Consistent with this effect the use of acetaminophen was significantly reduced in oseltamivir-treated patients.
Oseltamivir significantly reduced the occurrence of secondary complications during the study, notably otitis media. The 44% reduction observed in the incidence of otitis media is medically significant and was associated with reduced antibiotic usage. This benefit is of great value in the era of increasing antimicrobial resistance. The proportion of adult patients with influenza-related complications requiring antibiotic treatment was reduced by 50% in oseltamivir recipients. 13 In our study the hospitalization rate was very low, with no oseltamivir recipients requiring hospitalization during the study. This observation should be expected in otherwise healthy children.
Treatment with oseltamivir shortened the duration and severity of symptoms, such as cough or coryza, and caused a rapid decline in viral shedding. Hypothetically oseltamivir treatment might reduce the likelihood of spread of influenza to close contacts; this possibility requires specific study. In an earlier study amantadine and rimantadine antiviral therapy of the index case in families decreased the likelihood of infection in contacts by 30%. 24 Because oseltamivir carboxylate is primarily eliminated by renal excretion and because the glomerular filtration rate is higher in children than in adults, a larger dose of oseltamivir on a milligrams per kg basis is required in the pediatric population. The 2-mg/kg dose of oseltamivir used in this study provides exposure to the active metabolite oseltamivir carboxylate equivalent to that previously shown to be effective for the treatment of influenza in adults (75 mg twice a day). 20 In vivo data from animal studies of influenza viruses resistant to the class of neuraminidase inhibitors have previously documented that these strains are less infectious and less pathogenic than wild-type influenza virus. 22 Consistent with these observations children excreting these viruses did not have protracted disease. Children who excreted resistant virus did so only at the end of the treatment period and were uniformly culture-negative at the next time point (Day 10). Thus resistance appears to be a short lived phenomenon with no apparent clinical sequelae in this clinical trial. The nature of the virus strains that emerge during treatment suggests that the potential for transmission of resistant virus is very low, although this requires further investigation in clinical practice. Future investigations with neuraminidase inhibitors, as with other antiviral agents, must assess the potential for the development of resistance and the potential clinical implications.
Oseltamivir was well-tolerated in this study. Although emesis of mild or moderate intensity and that of short duration was reported more frequently in children taking oseltamivir, fewer than 1% of children withdrew from the study for this adverse event. Interestingly oseltamivir recipients experienced a lower incidence of diarrhea compared with placebo. Gastrointestinal disturbances such as emesis, nausea and diarrhea occur in as many as 40% of children with influenza. 25 Finally the development of natural protective serum antibodies postexposure in oseltamivir recipients demonstrated that the humoral immune response to infection was not affected by treatment.
In conclusion oseltamivir given within 48 h of onset of illness is an effective and well-tolerated therapy for acute influenza A and B illness in previously healthy children. Furthermore, and importantly, secondary complications were significantly decreased.
